Subcutaneous administration of nano- and microsuspensions of poorly soluble compounds to rats

References

• Wening K, Breitkreutz J. Oral drug delivery inn personalized medicine: unmet needs and novel approaches. Int J Pharm 2011;404:1–9
   PubMed Web of Science ®Google Scholar
• Rabinow BE. Nanosuspensions in drug delivery. Nat Rev 2004;3:785–96
   Google Scholar
• Yang W, Peters JI, Williamsill RO. Inhaled nanoparticles – a current review. Int J Pharm 2008;356:239–47
   PubMed Web of Science ®Google Scholar
• Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006;62:3–16
   PubMed Web of Science ®Google Scholar
• Jinno J-I, Kamada N, Miyake M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dog. J Control Release 2006;111:56–64
   PubMed Web of Science ®Google Scholar
• Kayser O, Olbrich C, Yardley V, et al. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003;254:73–5
   PubMed Web of Science ®Google Scholar
• Kumar MP, Rao YM, Apte S. Formulation of nanosuspensions of albendazole for oral administration. Curr Nanosci 2008;4:53–8
   Web of Science ®Google Scholar
• Patravale VB, Date AA, Kulkarni RM. Nanosuspensions a promising drug delivery strategy. J Pharm Pharmacol 2004;56:827–40
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Björkman J-A, Skantze P, Zachrisson H. Usefulness of a nanoparticle formulation to investigate some hemodynamic parameters of a poorly soluble compound. J Pharm Sci 2011;100:2194–202
   PubMed Web of Science ®Google Scholar
• Holback H, Yeo Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm Res 2011;28:1819–30
   PubMed Web of Science ®Google Scholar
• Yu SS, Lau CM, Thomas SN, et al. Size- and charge dependent non-specific uptake of PEGylated nanoparticles by macrophages. Int J Nanomed 2012;7:799–813
   PubMed Web of Science ®Google Scholar
• Fujii Y, Kanamaru T, Kikuchi H, et al. Improvement of low bioavailability of a novel factor Xa inhibitor through formulation of cationic activities in its oral dosage form. Int J Pharm 2011;421:244–51
   PubMed Web of Science ®Google Scholar
• Huang RB, Mocherla S, Heslinga MJ, et al. Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery. Mol Membr Biol 2010;27:312–27
   PubMed Web of Science ®Google Scholar
• Zhao Y, Sun X, Zhang G, et al. Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. ACS Nano 2011;5:1366–75
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist A, Strimfors M. Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. Drug Dev Ind Pharm 2011;37:243–51
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist A, Strimfors M. Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor – the importance of gastrointestinal pH and solubility for the in vivo exposure. Drug Dev Ind Pharm 2011;37:1036–42
   PubMed Web of Science ®Google Scholar
• Oussoren C, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III, influence of surface modification with poly(ethyleneglycol). Pharm Res 1997;14:1479–84
   PubMed Web of Science ®Google Scholar
• Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 2001;50:143–56
   PubMed Web of Science ®Google Scholar
• Lindfors L, Skantze P, Skantze U, et al. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir 2006;22:906–10
   PubMed Web of Science ®Google Scholar
• Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3–19
   PubMed Web of Science ®Google Scholar
• Jain JP, Modi S, Domb AJ, Kumar N. Role of polyanhydrides as localized drug carriers. J Control Release 2005;103:541–63
   PubMed Web of Science ®Google Scholar
• Hafeman AE, Li B, Yoshii T, et al. Injectable biodegradable polyurethane scaffolds with release of platelet-derived growth factor for tissue repair and regeneration. Pharm Res 2008;25:2387–99
   PubMed Web of Science ®Google Scholar
• Ghalanbor Z, Korber M, Bodmeier R. Improved lysozyme stability and release properties of poly(lactide-co-glycolide) implants prepared by hot-melt extrusion. Pharm Res 2010;27:371–9
   PubMed Web of Science ®Google Scholar
• Kumar Naraharisetti P, Yung Sheng Ong B, Wei Xie J, et al. In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma. Biomaterials 2007;28:886–94
   PubMed Web of Science ®Google Scholar
• Saltzmanand WM, Fung LK. Polymeric implants for cancer chemotherapy. Adv Drug Deliv Rev 1997;26:209–30
   PubMed Web of Science ®Google Scholar
• Dhanikulaand AB, Panchagnula R. Localized paclitaxel delivery. Int J Pharm 1999;183:85–100
   PubMed Web of Science ®Google Scholar
• Mishra PR, Shaal LA, Muller RH, Keck CM. Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm 2009;371:182–9
   PubMed Web of Science ®Google Scholar
• Pardeike J, Muller RH. Nanosuspensions a promising formulation for the new phospholipase A2 inhibitor PX-18. Int J Pharm 2010;391:322–9
   PubMed Web of Science ®Google Scholar
• Verma S, Gokhale R, Burgessa DJ. A comperative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm 2009;380:216–22
   PubMed Web of Science ®Google Scholar
• Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev 2011;63:456–69
   PubMed Web of Science ®Google Scholar
• Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004;113:151–70
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Nordmark A, Theilig S, Lindahl A. A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. Drug Dev Ind Pharm 2011;37:185–92
   PubMed Web of Science ®Google Scholar
• Hewitt H. The mechanics of subcutaneous injection. Br J Exp Pathol 1954;35:35–40
   PubMed Web of Science ®Google Scholar
• Cai SC, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 2011;63:901–8
   PubMed Web of Science ®Google Scholar
• Soeberg T, Rasmussen CH, Mosekilde E, Cilding-Jorgensen M. Absorption kinetics of insulin after subcutaneous administration. Eur J Pharm Sci 2009;36:78–90
   PubMed Web of Science ®Google Scholar
• Soeberg T, Rasmussen CH, Mosekilde E, Cilding-Jorgensen M. Bioavailability and variability of biphasic insulin mixtures. Eur J Pharm Sci 2012;46:198--208
   Google Scholar
• Porter CJH, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Phar Sci 2000;89:297–310
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, Porter CJH. Targeting the lymphatics using dendritic polymers (dendrimers). Adv Drug Deli Rev 2011;63:890–900
   PubMed Web of Science ®Google Scholar
• Lasic DD, Papahadjopoulos D. Liposomes revisted. Science 1995;267:1275–6
   PubMed Web of Science ®Google Scholar
• Oyen WJ, Boerman OC, Storm G, et al. Labelled stealth liposomes in experimental infection: an alternative to leukocyte scintigraphy? Nucl Med Commun 1996;17:742–8
   PubMed Web of Science ®Google Scholar
• Romberg B, Hennink WE, Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res 2008;25:55–71
   PubMed Web of Science ®Google Scholar
• Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997;28:5–24
   PubMed Web of Science ®Google Scholar
• Al-Tahami K, Oak M, Singh J. Controlled delivery of basal insulin from phase-sensitive polymeric systems after subcutaneous administration: in vitro release, stability, biocompatibility, in vivo absorption, and bioactivity of insulin. J Pharm Sci 2011;100:2161–71
   PubMed Web of Science ®Google Scholar
• Gasparini G, Kosvintsev SR, Stillwell MT, Holdich RG. Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification. Colloids Surf 2008;B61:199–207
   Google Scholar